Cyber Assault Takes Toll on Stryker's Quarterly Performance, Shares Slide

Table of Contents The medical device manufacturer delivered a challenging first-quarter performance, exceeding prior-year profit levels while falling short of analyst expectations for both revenue and earnings. The quarter’s outcome was significantly influenced by a cybersecurity breach that occurred in March. $SYK | Stryker Corp., Q1-2026 Earning Report pic.twitter.com/yvh17fBaD9 — Hardik Shah (@AIStockSavvy) April 30, 2026 Shares of SYK retreated roughly 2% in after-market activity to $308.75 after the earnings announcement. Stryker Corporation, SYK The medical technology firm recorded net earnings of $745 million, translating to $1.93 per share, representing an increase from the year-ago figure of $654 million, or $1.69 per share. However, adjusted earnings reached $2.60 per share, undershooting analyst expectations of $2.98. Quarterly revenue registered at $6.02 billion for the three-month period ending March 31. While this represented a 2.6% year-over-year advance, it remained below the Street’s consensus projection of $6.35 billion. During March, a hacking collective known as Handala, reportedly tied to Iran, took credit for launching a damaging cyberattack against the company. This security breach triggered extensive disruptions across the organization’s Microsoft infrastructure and allegedly postponed certain surgical procedures. Multiple employees and contracted workers shared on various social platforms that the hacking group’s emblem displayed on their computer login interfaces, though Reuters could not independently confirm these reports. The company had previously disclosed in April that the cybersecurity incident would negatively impact first-quarter financial results. Management confirmed this expectation during Thursday’s announcement. According to a Wall Street Journal article from that period, the cybercriminals stated they launched the attack as a response to growing tensions between the United States and Iran. Stryker’s MedSurg and Neurotechnology division, representing the company’s primary business unit, generated a 5% revenue increase to $3.21 billion. However, this figure disappointed compared to analyst projections of $3.83 billion. The Orthopaedics division delivered more encouraging results. Revenue climbed 6.3% to $2.81 billion, surpassing analyst estimates of $2.51 billion. Weaker customer demand for medical implants and equipment utilized in sophisticated procedures — particularly spinal surgeries and orthopedic interventions — contributed to the overall revenue underperformance. The company faces direct competition from Zimmer Biomet (ZBH) and Johnson & Johnson (JNJ) throughout the orthopedics marketplace, spanning categories including hip and knee replacement systems, trauma products, and sports medicine devices. Despite the quarter’s disappointing results, the medical device maker maintained its full-year financial projections. Management confirmed its previous expectations for adjusted annual earnings between $14.90 and $15.10 per share. This unchanged forecast suggests leadership believes the cybersecurity incident’s financial consequences are limited to the first quarter and will not materially affect full-year performance. With adjusted EPS of $2.60 for Q1 positioned against full-year guidance of $14.90–$15.10 per share, the company anticipates accelerated earnings growth throughout the remaining nine months. Management reaffirmed its full-year adjusted earnings per share guidance spanning $14.90 to $15.10 per share.